Full-Time
Senior Scientist
Supervisor
Updated on 8/19/2026
GRAIL
1,001-5,000 employees
Blood-based cancer detection via sequencing tests
Compensation Overview
$122k - $147k/yr
Durham, NC, USA
In Person
On-site five days per week required.
Bachelor's, Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to GRAIL
See people who can refer or advise you
- PhD in Molecular Biology, Biochemistry, Biotechnology, or a related scientific discipline with 2-5 years of relevant research or industry experience; or a Master's degree with 5-8 years of relevant experience; or a Bachelor's degree with 8+ years of relevant experience.
- Demonstrated expertise in molecular biology, protein chemistry, or related experimental approaches.
- Proven experience independently designing and executing experiments from concept through data interpretation.
- A strong record of technical research contributions demonstrated through publications, presentations, or project outcomes.
- Proficiency with relevant laboratory techniques and data analysis tools.
- Effective written and verbal communication skills for technical reports, publications, and presentations.
- Knowledge of applicable regulatory standards appropriate to the position's complexity and scope, including GMP quality management systems such as ISO 13485, clinical laboratory regulations such as CAP, CLIA, NYSDOH, and ISO 15189, and regulated medical device requirements such as IVDD, IVDR, FDA 21 CFR 800 series, and FDA 21 CFR Part 11.
- Ability to work in an office and laboratory environment with exposure to biological samples, chemicals, and laboratory equipment.
- Consistent use of personal protective equipment, including lab coats, gloves, and safety glasses.
- Ability to stand for extended periods and perform pipetting and laboratory equipment and sample handling.
- Independently design, plan, and execute experiments supporting platform troubleshooting, optimization, and other research objectives.
- Analyze, interpret, and present experimental results to identify root causes of platform performance issues and provide scientifically sound recommendations.
- Develop, optimize, and troubleshoot experimental methods, protocols, and workflows to improve platform performance, robustness, efficiency, and data quality.
- Investigate technical challenges, identify sources of variability, and implement corrective actions to ensure reliable platform operation.
- Provide day-to-day supervision, coaching, performance feedback, and career development for direct reports.
- Establish team priorities, allocate resources, and ensure timely execution of project deliverables.
- Prepare detailed technical reports, presentations, and documentation summarizing troubleshooting investigations, platform performance, and research findings.
- Collaborate with cross-functional teams to resolve platform-related issues and integrate findings into broader research and development strategies.
- Ensure compliance with laboratory safety, quality, and regulatory standards while maintaining platform reliability and operational excellence.
- Work extended hours when needed to meet deadlines or conduct time-sensitive experiments.
- Advanced technical and analytical skills for troubleshooting complex scientific problems.
- Strong organizational and project management abilities, including the ability to prioritize multiple projects.
- Ability to lead and mentor less-experienced team members.
- Ability to work effectively in cross-functional research environments.
- Ability to contribute to the development of new technologies and approaches.
GRAIL develops blood-based cancer tests that aim to detect cancer at its earliest stages. The tests use high-intensity sequencing to analyze large amounts of tumor genome data from a blood sample and apply advanced algorithms and deep learning to identify signals indicating cancer. Revenue comes from selling these tests to healthcare providers and research institutions, with potential expansion to direct-to-consumer sales in the future. Compared with others, GRAIL combines extensive sequencing data with clinical studies and sophisticated analytics to provide actionable cancer-detection results, focusing on early diagnosis. The company’s goal is to lower global cancer mortality by catching the disease early when treatment is more effective.
Company Size
1,001-5,000
Company Stage
Post IPO Equity
Headquarters
Menlo Park, California
Founded
2016
Get referred to GRAIL
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA advisory committee meets September 23, 2026 on Galleri PMA.
- First-half 2026 revenue grew about 30%, and test volume rose 42%.
- Digital-health, employer, and physician channels pushed more than 117,000 tests in 2026.
What critics are saying
- NHS-Galleri missed its primary endpoint on February 19, 2026, crushing shares 50.55%.
- Robbins v. GRAIL alleges securities fraud, extending legal overhang through 2026.
- No FDA approval exists yet; a September rejection would cripple reimbursement and adoption.
What makes GRAIL unique
- Galleri screens 50-plus cancers from one blood draw using methylation and sequencing.
- GRAIL owns a huge automated lab capable of over one million tests annually.
- Samsung backs South Korea commercialization with a $110 million strategic investment.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -4%GRAIL highlights Galleri growth ahead of key FDA advisory meeting. August 14, 2026 GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices. Speaking at the Canaccord Genuity Growth Conference, Freidin said GRAIL generated approximately 30% revenue growth and 42% test-volume growth in the first half, with more than 117,000 tests completed. The company has been focused on building a market for Galleri through self-pay and reimbursement-related channels, including digital health providers, self-insured employers and traditional physician practices. "The things really driving growth right now are traction in those channels, and then the education of those sales reps now having the ASCO data in hand," Freidin said, referring to data from the NHS-Galleri study presented at the American Society of Clinical Oncology meeting. Sales force and digital health expansion. GRAIL expanded its sales force during the second quarter and completed training by the end of the period, Freidin said. Sales representatives have also been trained on the NHS-Galleri results and are using the data in physician discussions. The company's integrations with Quest Diagnostics and athenahealth have been in place for more than a year, according to Freidin. He said ordering becomes easier once physicians are familiar with the test and have experience detecting cancers through it. GRAIL expects to integrate with Epic by the end of the year, which Freidin said should further reduce ordering friction. Discover more Stock profit calculator Stock market news Digital health represents a significant opportunity, he said. GRAIL's partner Function targets consumers who are proactive about their health, a customer profile that aligns with cancer screening before symptoms emerge. Freidin said digital-health channel volumes doubled year over year on a quarterly basis. GRAIL also launched with Hims & Hers earlier in the year, though Freidin said that company's attention has been more focused on its GLP-1 business than its laboratory offerings. He characterized additional investment by Hims & Hers in its labs business as a potential source of future upside. Pricing, margins and capacity. Galleri's patient-pay price is about $950, while GRAIL reported an average selling price of roughly $700 per test, according to the conference discussion. Freidin said the company began using volume-based contracts with physicians, health systems and employers last year, lowering prices as volumes rise. He said GRAIL expects the eventual Centers for Medicare & Medicaid Services reimbursement rate to be around $500. At that price, the company believes it can operate with gross margins of 50% to 60% at scale using the current version of its test. GRAIL's laboratory can process more than 1 million tests annually, Freidin said, compared with an implied annualized volume of about 240,000 tests based on first-half activity. The company is therefore focused on gaining leverage from its fixed-cost infrastructure. He described the lab as highly automated, with limited manual handling after sample tubes enter the processing workflow. FDA review and clinical data. Freidin said GRAIL's upcoming Food and Drug Administration advisory committee meeting is expected to focus on Galleri's performance and efficacy data. The company submitted Galleri for premarket approval in January 2026, and the advisory committee meeting is scheduled for Sept. 23. He said GRAIL has had an "iterative and collaborative" review process with the FDA and expects the advisory committee discussion to address measures such as positive predictive value, specificity and cancer signal detection rate. Freidin said the company is preparing for a range of possible outcomes from the meeting. GRAIL has emphasized results from the NHS-Galleri trial, which did not meet its primary endpoint but showed more than a 20% reduction in stage IV cancers, according to Freidin. The study also found more stage I and II cancers, and he said the results reflected a greater-than-expected amount of stage III cancer already present in the population at baseline. Freidin said the findings have resonated with oncologists because earlier-stage cancers may more often be treated with curative intent. He added that the company plans an additional 12 months of follow-up in the NHS-Galleri study, with data expected in the first half of 2027. A nested mortality analysis is expected to read out sometime in 2028. The company also submitted results from its PATHFINDER 2 study to the FDA. Freidin said the study, which included about 35,000 participants, showed that Galleri's performance in an intended-use screening population remained consistent with or improved from the earlier PATHFINDER study. Reimbursement and international plans. Freidin said GRAIL is in early discussions with CMS regarding potential national coverage after FDA approval. He said the REACH study, designed for the Medicare population, will be important to those discussions because it is evaluating clinical utility and reductions in late-stage disease. The study was originally designed to read out in 2030 or 2031, although GRAIL may provide data along the way. Internationally, GRAIL is discussing next steps with the U.K.'s National Health Service. Freidin said the NHS has reviewed the data, but decisions will also involve political and budget considerations and are not expected to move quickly. The company also completed a $110 million financing associated with its Samsung agreement in June. The arrangement will initially involve Samsung establishing a sales force in Korea and selling Galleri tests into that self-pay market, with samples sent back to GRAIL. If the initial phase is successful and GRAIL receives FDA approval, the partnership could expand to Japan and potentially include a laboratory buildout. GRAIL ended the quarter with about $900 million in cash, Freidin said. The company expects cash burn of less than $300 million for the year but may continue investing in sales and commercial infrastructure if demand proves durable ahead of broader reimbursement. About GRAIL (NASDAQ:GRAL). GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri(TM) test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up. Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GRAIL, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list. While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
GRAIL reported second-quarter revenue of $44.7 million, up 26% year-over-year, driven by higher Galleri test volumes. The company sold more than 61,000 Galleri tests during the quarter, a 35% increase from the prior year. Screening revenue contributed $42.6 million, up 24%, whilst development services revenue totalled $2 million. For the first half of the year, screening revenue exceeded $80 million, up 30%, with test volume surpassing 117,000 tests. GRAIL reported a net loss of $110.2 million, down 3% from the previous year. The company ended the quarter with $861.6 million in cash, including a $110 million investment from Samsung that closed in June. The company has submitted its premarket approval application to the FDA and expects an advisory committee review in autumn.
News for rocket scientists. GRAIL, Inc. sued for securities Law violations - contact the DJS Law Group to discuss your rights - GRAL. LOS ANGELES, July 31, 2026 /PRNewswire/ - The DJS Law Group reminds investors of a class action lawsuit against GRAIL, Inc. ("Grail" or "the Company") (NASDAQ: GRAL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GRAL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: May 13, 2025 to February 19, 2026 DEADLINE: August 4, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Grail described its NHS-Galleri trial in positive terms while concealing adverse facts about the trial's results. Based on these facts, Grail's public statements were false and materially misleading throughout the class period. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. Really Rocket Science specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Its clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of its clients are extraordinarily valuable assets that demand respect, focus, and results. David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 SOURCE DJS Law Group LLP
$GRAL securities: suffer losses on your GRAIL, Inc. investment? BFA Law reminds investors of the Securities Fraud lawsuit to recover losses. A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial, potentially violating federal securities laws. NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit. Key Details of the GRAIL ($GRAL) Class Action: * Lead Plaintiff Deadline: August 4, 2026 * Alleged Misconduct: Securities fraud relating to GRAIL's NHS-Galleri cancer trial * Stock Drop: February 20, 2026 - 50.55% Stock Drop * Court: U.S. District Court for the Northern District of California * Action: Contact BFA Law to discuss your rights Investors have until August 4, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GRAIL common stock. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned Robbins v. GRAIL, Inc., et al., No. 26-cv-05428. Why is GRAIL Being Sued for Securities Fraud? GRAIL is a commercial-stage healthcare company focused on early cancer detection. GRAIL developed Galleri, a multi-cancer early detection test that analyzes blood samples to screen for multiple cancers, identify the likely organ or tissue of origin, and assist in the screening process. As part of GRAIL's efforts to attain an accelerated implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not." According to the complaint, during the relevant period, GRAIL made positive statements about Galleri, the NHS-Galleri trial design, and top-line results from the first screening round, including that the NHS-Galleri trial was "designed with three consecutive years of screening in order to achieve the primary endpoint," and that "Galleri is working in the real world." As alleged, in truth, the NHS-Galleri trial's three-year timeframe was insufficient to demonstrate the primary endpoint. Why did GRAIL's Stock Drop? On February 19, 2026, GRAIL announced top-line results from its NHS-Galleri trial. Although the Company emphasized certain favorable results, GRAIL disclosed that the trial did not meet its primary endpoint. Specifically, GRAIL stated that the "primary endpoint of statistically significant Stage III-IV reduction was not observed." GRAIL attributed the disappointing outcome, in part, to "probably need[ing] a longer follow-up time to be able to [compare the two arms of the study] adequately." This news caused the price of GRAIL stock to decline $51.32 per share, or 50.55%, from a closing price of $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026. What Can You Do? If you invested in GRAIL, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Today in New York do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
GRAIL to present at the Canaccord Genuity 46th Annual Growth Conference. Jul 30, 2026, 16:01 ET MENLO PARK, Calif., July 30, 2026 /PRNewswire/ - GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, Aug. 11 at 10:00 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAIL GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. SOURCE GRAIL, Inc.